This Study Review is a summary of 5-year efficacy and safety data from an extension study of the 1-year
SCULPTURE study1 of fixed-interval (FI) versus retreatment-as-needed (RAN) secukinumab therapy in patients
with moderate-to-severe plaque psoriasis. Extension data out to 3 years were published previously,2 and
5-year data were presented recently at the 26th European Academy of Dermatology and Venereology Congress
(September 13–17, 2017), Geneva, Switzerland. The current Study Review provides a detailed overview of the
5-year extension data for secukinumab; this analysis is the first phase 3 study evaluating efficacy and safety
of an interleukin (IL)-17A inhibitor (at its approved dosage) out to 5 years of treatment.
Independent commentary is provided by Associate Professor Peter Foley, Director of Research at the Skin
and Cancer Foundation and the Head of Dermatology Research at St. Vincent's Hospital Melbourne.
Please login below to download this issue (PDF)